ArticleOncogene2005
Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 79 citations in OpenAlex.
- Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.eLife · 2025Observational
- PTTG1: a Unique Regulator of Stem/Cancer Stem Cells in the Ovary and Ovarian Cancer.Stem cell reviews and reports · 2019Article
- Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer.Oncogene · 2017Article
- Inhibition of PTTG1 expression by microRNA suppresses proliferation and induces apoptosis of malignant glioma cells.Oncology letters · 2016Article
- PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.Journal of hematology & oncology · 2015Article
- Pituitary tumor transforming gene PTTG2 induces psoriasis by regulating vimentin and E-cadherin expression.International journal of clinical and experimental pathology · 2015Article
- Cdc20 and securin overexpression predict short-term breast cancer survival.British journal of cancer · 2014Article
- Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells.Frontiers in endocrinology · 2014Review
- Thyroid hormone receptors and cancer.Biochimica et biophysica acta · 2013Review
- Thyroid hormone actions in liver cancer.Cellular and molecular life sciences : CMLS · 2013Review
- Article
- The pituitary tumor transforming gene in thyroid cancer.Journal of endocrinological investigation · 2012Review
- Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment.Cancer research · 2011Article
- Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Pathogenesis of pituitary tumors.Nature reviews. Endocrinology · 2011Review
- Fifteen years' experience in thyroid surgery.Annals of the Royal College of Surgeons of England · 2010Article
- Pituitary senescence: the evolving role of Pttg.Molecular and cellular endocrinology · 2010Review
- Pituitary tumor transforming gene binding factor: a new gene in breast cancer.Cancer research · 2010Article
- Molecular aspects of thyroid hormone actions.Endocrine reviews · 2010Review
- E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors.Molecular endocrinology (Baltimore, Md.) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer reflects the progressive accumulation of genetic alterations and subsequent genetic instability of cells. Cytogenetic studies have demonstrated the importance of aneuploidy in differentiated thyroid cancer development. The pituitary tumour transforming gene (PTTG), also known as securin, is a mitotic checkpoint protein which inhibits sister chromatid separation during mitosis. PTTG is highly expressed in many cancers and overexpression of PTTG induces aneuploidy in vitro. Using fluorescent intersimple sequence repeat PCR (FISSR-PCR), we investigated the relationship between PTTG expression and the degree of genetic instability in normal and tumorous thyroid samples. The genomic instability index (GI index) was 6.7-72.7% higher in cancers than normal thyroid tissues. Follicular thyroid tumours exhibited greater genetic instability than papillary tumours (27.6% (n=9) versus 14.5% (n=10), P=0.03). We also demonstrated a strong relationship between PTTG expression and the degree of genetic instability in thyroid cancers (R2=0.80, P=0.007). To further investigate PTTG's role in genetic instability, we transfected FTC133 thyroid follicular cells and observed increased genetic instability in cells overexpressing PTTG compared with vector-only-transfected controls (n=3, GI Index VO=29.7+/-5.2 versus PTTG=63.7+/-6.4, P=0.013). Further, we observed a dose response in genetic instability and PTTG expression (GI Index low dose (0.5 microg DNA/ six-well plate) PTTG=15.3%+/-1.7 versus high dose (3 microg DNA) PTTG=50.8%+/-3.3, P=0.006). Overall, we describe the first use of FISSR-PCR in human cancers, and demonstrate that PTTG expression correlates with genetic instability in vivo, and induces genetic instability in vitro. We conclude that PTTG may be an important gene in the mutator phenotype development in thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.